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Vascular repair and regulation in kidney disease: Overview
The International Society of Nephrology (ISN) Fore-
fronts in Nephrology Conference entitled “Vascular
Repair and Regulation in Kidney Disease” was held
September 30, 2004, to October 2, 2004, in Dresden,
Germany.
In the opening presentation, Michael Goligorsky
(Valhalla, New York) considered the concept of en-
dothelial dysfunction in historical perspective (see fol-
lowing article). He also presented in-depth recent find-
ings concerning the way(s) by which homocysteine, asym-
metric dimethylarginine (ADMA), advanced glycation
end products (AGEs), and 3-nitrotyrosine–modified pro-
teins are instrumental in contributing to endothelial
dysfunction.
Kerstin Amann (Erlangen-Nu¨rnberg, Germany) ana-
lyzed the ramifications of uremia-related atherosclerosis
in experimental animals. In rats, endothelin antagonists
were of particular usefulness in preventing artheroscle-
rotic uremic arterial remodeling. In addition in her ex-
periments, bone morphogenetic protein-7 (BMP-7) was
able to prevent vascular calcification. Uremia was also as-
sociated with increased plaque size, increased oxidative
stress in the vessel wall, and an augmented expression of
adhesion molecules on the endothelium.
Bengt Lindholm (Stockholm, Sweden) discussed the
incidence of arteriosclerosis in end-stage renal disease
(ESRD), the multiple factors involved and the pu-
tative roles of specific molecules such as C-reactive
protein (CRP), interleukin (IL)-6, and myeloperoxi-
dase (MPO) in causing inflammation and arteriosclero-
sis. As for treatment, Dr. Lindholm mentioned statins,
angiotensin-converting enzyme (ACE) inhibitors, perox-
isome proliferators-activated receptor-c (PPAR-c) acti-
vators, tocopherols, and N-acetylcysteine.
The following session was dedicated to oxidative stress.
Michael Wolin (Valhalla, New York) described external
conditions, such as age and hypertension as causative
factors increasing superoxide formation (see following
article). He analyzed the different nicotinamide adenine
dinucleotide phosphate (NADPH) oxidases and their
regulation.
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Ralf Brandes (Frankfurt, Germany) said that all cus-
tomary methods of determination of oxidative stress (di-
rect measurements of radicals, determination of reaction
products of radicals, effects on signal transduction, effects
on gene expression, assays for antioxidative capacity, ac-
tivity of antioxidative enzymes, activity of radical gen-
erating enzymes) are unsatisfactory if used alone (see
following article). He suggested that at least two inde-
pendent methods were needed to make valid statements
about oxidative stress.
Thomas Mu¨nzel (Mainz, Germany) demonstrated en-
dothelial dysfunction in an animal model of hyperten-
sion due to angiotensin infusion. He showed that the
latter increased protein kinase C (PKC) activity leading
to enhanced NADPH oxidase activity and more super-
oxide generation. This in turn leads to endothelial ni-
tric oxide synthase (eNOS) uncoupling via generation
of peroxinitrite and ADMA. eNOS uncoupling was the
cause of the endothelial dysfunction. Incidentally he also
addressed nitrate tolerance. He advanced data show-
ing that nitrate tolerance too was attributable to eNOS
uncoupling, which was due to THB4 “deficiency” from
tetrahydrobiopterin (THB4) oxidation, both amenable to
treatment with folic acid and THB4.
Jan Galle (Wu¨rzburg, Germany) discussed oxidative
stress in chronic renal failure. Amongst the causes of
oxidative stress he mentioned endogenous stimuli [an-
giotensin II, oxidized low-density lipoprotein (oxLDL),
lipopolysaccharide (LPS), AGEs, hyperhomocysteine-
mia] and exogenous ones (endotoxin from dialysate and
blood/membrane contact). He indicated specifically that
oxLDL was damaging in that it caused endothelial dys-
function via NADPH oxidase activation, calcium sensiti-
zation of vascular smooth muscle cells (VSMCs) via rho
kinase activation and apoptosis of vascular cells by direct
superoxide action. Beyond statins and reactive oxygen
species (ROS) inhibitors, he recommended the use of ul-
trapure water, biocompatible membranes, elimination of
smoking, optimization of hygienic conditions, correction
of anemia, and avoidance of iron overload.
Another session focused on nitric oxide. Patrick Val-
lance (London, United Kingdom) discussed the biochem-
istry of ADMA and its relevance in uremia and cardio-
vascular disorders. He suggested that ADMA is effective
in changing genetic programs. For example, ADMA was
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shown to alter BMP signaling and osteocalcin at the ge-
netic level.
Jens Passauer (Dresden, Germany) tackled the con-
troversies surrounding the role of nitric oxide in ure-
mic endothelial dysfunction (see following article). He
concluded that baseline nitric oxide generation was nor-
mal in uremia, whereas agonist-induced nitric oxide gen-
eration (e.g., by infusing acetylcholine) was subnormal,
if functional testing of forearm resistance vessels was
employed. He suggested that eNOS uncoupling or ni-
tric oxide consumption byproducts of oxidative stress
might be involved in causing the deficient nitric oxide
function.
Ingrid Fleming (Frankfurt, Germany) had been asked
to analyze the regulation of eNOS. She concentrated on
three aspects: (1) shear stress [or vascular endothelial
growth factor (VEGF)-induced eNOS activation (involv-
ing PT3K and Akt)]; (2) bradykinin-induced eNOS acti-
vation (calmodulin); and (3) the multiple pathways of
eNOS down-regulation by oxLDL (involving intracellu-
lar redistribution of eNOS, defective calmodulin binding,
and dephosphorylation of eNOS on Thr495).
Malte Kelm (Du¨sseldorf, Germany) reviewed evidence
on whether there is a circulating pool of nitric oxide. He
considers nitrite in human blood—a degradation product
of nitric oxide—to be a diagnostic tool, being related to
nitric oxide production and in proportion to the number
of cardiovascular risk factors in patients. He showed ex-
periments in which an intravenous application of nitric
oxide into the brachial artery on one side (in human vol-
unteers) was followed several minutes later first by an
increase of measurable circulating nitroso compounds in
the contralateral arm followed a short time later by fore-
arm vasodilation on that (contralateral) side. As nitroso
compounds possibly storing and transporting nitric oxide,
he considered the following: albumin, hemoglobin, and
nitrated lipids.
Diabetic nephropathy was also an issue in a separate
session. Angelika Bierhaus (Heidelberg, Germany) dis-
cussed recent findings, including those from her own lab-
oratory on the AGE/receptor for AGE (RAGE)/nuclear
factor-jB (NF-jB) axis. In experimental diabetes mel-
litus there are now knockout models in the mouse
(including a RAGE−/− mouse) that appear to be help-
ful in further analyzing the role(s) of RAGE and AGE.
In these models, Bierhaus’ group finds evidence that
AGE/RAGE contribute to the development of late di-
abetic complications, such as neuropathy, which is ame-
liorated in the RAGE−/− mouse. The renal changes in
RAGE−/− diabetic mice have not been demonstrated,
yet. However, blockade of RAGE by “treatment” with
soluble RAGE given parenterally reduced albuminuria
and increased creatinine clearance in a diabetic mouse
model. In a similar vein, using blockade of RAGE by
s-RAGE or using RAGE−/− knockout models it was
shown that denudation induced arteriosclerosis was in-
hibitable by those maneuvers.
Hi Bahl Lee (Seoul, Korea) described diabetic
nephropathy, as it relates to ROS, signaling, and ma-
trix remodeling. He stressed the dramatic increase
projected globally until 2030. Present treatments delay
onset and progression of diabetic nephropathy but do
not stop them from occurring. High glucose induces re-
nal injury by induction of ROS, which, in turn, leads
to extracellular matrix (ECM) accumulation. Diabetic
glomeruli show intense ROS-related signals. ROS gen-
eration in mesangial cells is dependent on (inhibitable?)
PKC activation and NADPH oxidase stimulation, both of
which appear to be interrelated. ROS are also involved
in NF-jB activation in mesangial cells exposed to high
glucose. Antioxidants (melatonin) and superoxide dis-
mutase (SOD) protectively inhibited some of the patho-
logic alterations.
Endothelial cells are involved in renal angiogenesis
and glomerular function. Bo¨rje Haraldsson (Gothenburg,
Sweden) reviewed the role of glomerular endothelium
in the glomerular filtration barrier. The glomerular en-
dothelial cell surface coat “glycocalyx” is an important
component of this barrier. Production of glycosamino-
glycans by endothelial cells is highly dynamic. Impair-
ment of size and charge selectivity of the glomerular
filtration barrier due to impaired production of gly-
cosaminoglycans is one feature of endothelial dysfunc-
tion. Dr. Haraldsson and his colleagues developed a new
heterogenous charged fiber model to estimate size and
charge selectivities in vivo. Experimental destruction of
glycocalyx by hyaluronidases administered to a mouse
model resulted in a remarkable loss of barrier function
with proteinuria.
Barbara Ballermann (Edmonton, Canada) described
the regulation of glomerular endothelial cell growth (see
following article).
Wolfgang Fierlbeck (Frankfurt, Germany) discussed
the role of apoptosis during organ development. He fo-
cused on the lumen formation of glomerular capillaries.
Transforming growth factor-b (TGF-b) plays a crucial
role for lumen formation by initiating apoptosis of re-
dundant endothelial cells within the compact endothelial
cell mass. A subset of surviving endothelial cells orga-
nizes into tubes. Labeling of apoptotic cells within the
glomerular capillary with antibodies against endothelial
surface markers demonstrated their endothelial origin.
Inhibition of TGF-b1 by neutralizing antibodies during
organogenesis in vivo resulted in reduced lumen forma-
tion of the glomerular capillary and in retention of undif-
ferentiated endothelial cells. Furthermore, the frequency
of apoptotic endothelial cells within the capillary lumen
was reduced.
Marianne C. Verhaar (Utrecht, The Netherlands)
discussed the role of bone marrow–derived cells in
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endothelial repair. Using the anti-Thy 1.1 nephritis mouse
model they could demonstrate that a significant number
of bone marrow–derived cells contribute to the glomeru-
lar endothelial cell turnover.
Danilo Fliser (Hannover, Germany) showed that ery-
thropoietin (EPO) is not only the main stimulator of ery-
thropoesis but also contributes to the development of
endothelial progenitor cells (EPC). A possible under-
lying mechanism is the stimulation of protein kinase B
(Akt) via the EPO receptor. Akt in turn is known to
stimulate eNOS. Recombinant human EPO in a dose
that did not augment hematocrit increased the number
of circulating EPC in humans as well as their ability to
form tubes within matrigel in vitro. Treatment with re-
combinant EPO in vivo offers the possibility of tissue
protection as demonstrated by a prolonged preservation
of renal function in the 5/6 nephrectomized rat or the
improved neovascularization in the rat after hind limb
ischemia.
Ulrich Laufs (Homburg, Germany) reported an in-
creased number of circulating EPC after physical exer-
cise in mice. The training effect was completely abol-
ished by systemic blockade of NOS with L-NMMA
and in eNOS knockout mice demonstrating a crucial
role of eNOS in EPC regulation. Furthermore, physi-
cal exercise improved vascular reactivity in response to
the endothelium-dependent vasodilator acetylcholine in
these mice. The vasodilatation was nitric oxide–mediated.
The authors found an improved neoangiogenesis and a
reduced neointima formation after exercise. The stim-
ulating effects of physical training on the number of
circulating EPC were confirmed in a study of healthy vol-
unteers as well as in patients with coronary artery disease.
However it still remains to be clarified whether circulat-
ing EPC are the prerequisite for endothelial repair and
intact endothelial function or not.
Carmen Urbich (Frankfurt, Germany) reviewed the
function of EPC in patients with arteriosclerosis. She re-
ported stimulatory effects of statin therapy on these cells
(see following article).
Marlies Elger (Hannover, Germany) reported the pos-
sibility of nephrogenesis and glomerulogenesis in the
adult little skate. Obviously, there are persisting renal
stem cells in a privileged sector of the adult kidneys of
these lower vertebrates.
With a focus on kidney and pancreas Marc Hammer-
man (St. Louis, Missouri) described metanephroi and of-
fered new possibilities for xenotransplantation of these
organs at an early stage of organogenesis (see following
article).
Using atomic force microscopy Hans Oberleithner
(Muenster, Germany) could demonstrate an increase of
endothelial cell surface area and stiffness induced by
treatment with aldosterone (see following article). These
effects were completely reversed by spironolactone.
Ralf Dechend (Berlin, Germany) reviewed the patho-
genesis of preeclampsia. They identified functionally ac-
tive autoantibodies against the angiotensin II type 1 re-
ceptor. They demonstrated an autoantibody induced in-
duction of NADPH oxidase and in turn of NF-jB in
the placenta of preeclamptic women. Furthermore, they
demonstrated an impaired endothelial function in women
with a susceptibility to preeclampsia. Possible causes con-
sidered were circulating ADMA, up-regulation of an-
tiangiogenic factors such as sFlt1 (soluble receptor for
VEGF) and decreased circulating levels of VEGF. The
clinical relevance of these findings has yet to be eluci-
dated.
Martin Tepel (Berlin, Germany) focused on the effects
of an antioxidant treatment with acetylcysteine and vita-
min E in uremic patients. Uremia is associated with in-
creased production of ROS. Two clinical studies showed
a clear benefit of either treatment (acetylcysteine or vi-
tamin E) compared to placebo regarding the composite
end point of death, myocardial infarction or intervention
for coronary or peripheral artery disease in patients with
ESRD. Possible underlying mechanisms are a reduction
of oxLDL or of homocysteine.
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